HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
21 hedge funds and large institutions have $3.22M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 3 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
17% more funds holding
Funds holding: 18 → 21 (+3)
51% less capital invested
Capital invested by funds: $6.59M → $3.22M (-$3.37M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$729K |
| 2 |
LCM
Laurion Capital Management
New York
|
+$412K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$231K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$152K |
| 5 |
VF
Virtu Financial
New York
|
+$133K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$3.27M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$541K |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$4K |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$380 |
HTGM Hedge Fund Activity: Q3 2017 in Review
21 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q3 2017, worth a combined $3.22M — down 51% from $6.59M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new HTGM positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 1 trimmed.
The largest buyer was Granahan Investment Management, adding an estimated $729K. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $3.27M sold.
- 21 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q3 2017, up from 18 in Q2 2017.
- Funds reported $3.22M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q3 2017, down 51% quarter-over-quarter.
- 7 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q3 2017 and 3 closed out, a net change of +4 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q3 2017 was Granahan Investment Management, an estimated $729K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q3 2017 was Novo Holdings A/S, an estimated $3.27M sold.
Based on aggregated 13F filings for Q3 2017.